Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

NCT04064346 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class

Stopped The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with autosomal dominant polycystic kidney disease (ADPKD).

Conditions

Interventions

Sponsor

Palladio Biosciences

Collaborators